Walden
PrivateLast Round
Series A
Oct 6, 2020
Total Funding Raised
$51M
Company Overview
Walden Biosciences is a biopharmaceutical company focused on developing targeted therapies for kidney diseases, including chronic kidney disease and acute kidney injury, by manufacturing medicines that act directly on specific cells within the kidney.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Walden Comps
Public and private peers based on sector, stage, and business model.
Walden Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2020 |
Key People
Founding team and executive leadership
Walden Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| ARCH Venture Partners | Series A |
| ATEM Capital | Series A |
| Pandect Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 28, 2025
Howard Mayer, M.D. appointed to the Board of Directors.
Walden Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Walden's valuation, stock price, and market status.
